Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;17(4):371-381.
doi: 10.2174/0118744710300495240409074900.

Hypofractionated Radiation Therapy Suppresses Radioresistance in U87 Human Glioma Cells by Inhibiting Yap1 and Hsp90 Proteins

Affiliations
Free article

Hypofractionated Radiation Therapy Suppresses Radioresistance in U87 Human Glioma Cells by Inhibiting Yap1 and Hsp90 Proteins

Imran Khan et al. Curr Radiopharm. 2024.
Free article

Abstract

Background: Radiotherapy plays a vital role in the management of high-grade gliomas. However, the radio resistance of glioma cells limits the effect of radiation and drives recurrence inside the irradiated tumor volume leading to poor outcomes for patients.

Methods: High-grade glioma cell radioresistance significantly contributes to radiotherapy failure, highlighting the importance of identifying predictive biomarkers for radioresistance. An increasing body of evidence complies with the Yes Associated Protein 1 (Yap-1) and heat shock protein 90 (Hsp90) as biomarkers for radioresistance in glioma cells. A number of studies suggest the potential of radioresistance-associated factors as biomarkers and/ or novel therapeutic targets in glioma cells. Thus, it is essential for glioblastoma patients to identify robust druggable targets involved in radioresistance, optimizing irradiation protocol, and understanding their underlying molecular mechanisms.

Results: Therefore, in the present study, we hypothesized that hypofractionated Gamma Knife radiation therapy (HF-GKRT) could target Yap-1 and Hsp90 and downregulate the mechanism of radioresistance in high-grade glioma cells.

Conclusion: For this purpose, expression levels of radioresistance markers Yap-1 and Hsp90 were evaluated after treatment with HF-GKRT, and this was compared with single fraction Gamma Knife radiation therapy (SF-GKRT) in U87MG primary human glioblastoma cell line model. This would help design a novel radiation therapy regimen for glioblastoma patients by reducing the risk of radioresistance.

Keywords: Radioresistance; apoptosis.; gamma knife; glioblastoma; hypofractionated radiation; stereotactic radiation therapy.

PubMed Disclaimer

Similar articles

References

    1. Louis D.N.; Molecular pathology of malignant gliomas. Annu Rev Pathol 2006,1(1),97-117 - DOI - PubMed
    1. Stupp R.; Hegi M.E.; Mason W.P.; van den Bent M.J.; Taphoorn M.J.B.; Janzer R.C.; Ludwin S.K.; Allgeier A.; Fisher B.; Belanger K.; Hau P.; Brandes A.A.; Gijtenbeek J.; Marosi C.; Vecht C.J.; Mokhtari K.; Wesseling P.; Villa S.; Eisenhauer E.; Gorlia T.; Weller M.; Lacombe D.; Cairncross J.G.; Mirimanoff R.O.; Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009,10(5),459-466 - DOI - PubMed
    1. Stupp R.; Mason W.P.; van den Bent M.J.; Weller M.; Fisher B.; Taphoorn M.J.B.; Belanger K.; Brandes A.A.; Marosi C.; Bogdahn U.; Curschmann J.; Janzer R.C.; Ludwin S.K.; Gorlia T.; Allgeier A.; Lacombe D.; Cairncross J.G.; Eisenhauer E.; Mirimanoff R.O.; Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005,352(10),987-996 - DOI - PubMed
    1. Bleehen N.M.; Stenning S.P.; A medical research council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br J Cancer 1991,64(4),769-774 - DOI - PubMed
    1. Yazici G.; Cengiz M.; Ozyigit G.; Eren G.; Yildiz F.; Akyol F.; Gurkaynak M.; Zorlu F.; Hypofractionated stereotactic reirradiation for recurrent glioblastoma. J Neurooncol 2014,120(1),117-123 - DOI - PubMed

MeSH terms

Substances